Menu
Recruiting NCT03845036

The Effects of Diet and Exercise Interventions in Peripheral Artery Disease

No phase Interventional Claudication Peripheral Artery Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: DASH Diet plus Home-Based Exercise, Home-Based Exercise.
Who it may be relevant to
Registry conditions: Claudication, Peripheral Artery Disease. Basic parameters: from 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study is a 3-month, prospective, randomized controlled clinical trial designed to address the efficacy of the DASH dietary program combined with a home-based exercise program, quantified by a step activity monitor, to improve exercise and vascular outcome measures in patients with PAD.

Detailed description

This study seeks to (1) compare the changes in 6-minute walk distance (6MWD) and physical function quality of life in patients with peripheral artery disease (PAD) following a combined intervention of the dietary approaches to stop hypertension (DASH) dietary program plus a home-based exercise program, and following a home-based exercise program alone; and (2) compare the changes in microvascular function and inflammation in patients following the combined DASH diet and home-based exercise program, and the home-based exercise program alone.

The investigators hypothesize that the combined DASH diet and exercise program will result in greater increases in 6MWD and in the physical function quality of life than the exercise program alone. Further, it is hypothesized that the combined DASH diet and exercise program will result in greater improvements in calf muscle oxygen saturation \[StO2\] following exercise, and in high-sensitivity C-reactive protein (hsCRP\]) than the exercise program alone.

The home-based exercise program consists of intermittent walking to moderate claudication pain in a home-based setting. The DASH dietary program consists of the dietary approaches to stop hypertension diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy.

Interventions

  • Behavioral DASH Diet plus Home-Based Exercise
    The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
  • Behavioral Home-Based Exercise
    The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.

Primary outcome measures

  • Peak Walking Time [Time frame: 3 months]
  • Physical Function subscale of quality of life from the Medical Outcomes Study Short-Form 36 questionnaire [Time frame: 3 months]
Secondary outcome measures (3)
  • calf muscle oxygen saturation [Time frame: 3 months]
  • 6-minute walk distance [Time frame: 3 months]
  • high-sensitivity C-reactive protein [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • History of claudication,
  • Presence of PAD, defined by meeting at least one of the following criteria (ABI at rest < 0.90, or > 20% decrease in ABI following a heel-rise exercise test in patients with a normal ABI at rest (> 0.90), or history of peripheral revascularization.

Exclusion criteria

  • absence of PAD, defined by meeting all of the following 3 criteria (ABI at rest > 0.90), < 20% decrease in ABI following a heel-rise exercise test, and no history of peripheral revascularization,
  • non-compressible vessels (ABI > 1.40),
  • rest pain due to PAD (Fontaine stage III; Rutherford Grade II),
  • tissue loss due to PAD (Fontaine stage IV; Rutherford Grade III),
  • use of medications indicated for the treatment of intermittent claudication (cilostazol and pentoxifylline) initiated within three months prior to investigation,
  • peripheral revascularization within one month prior to investigation,
  • active cancer,
  • end stage renal disease defined as stage 5 chronic kidney disease,
  • medical conditions that are contraindicative for exercise according to the American College of Sports Medicine,
  • cognitive dysfunction (mini-mental state examination score < 24), and
  • failure to complete the baseline tests within three weeks.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • O'Donoghue Research Building, University of Oklahoma Health Sciences Center — Oklahoma City

Publications

  • Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation. 2011 Feb 8;123(5):491-8. doi: 10.1161/CIRCULATIONAHA.110.963066. Epub 2011 Jan 24. PMID 21262997
  • Gardner AW, Parker DE, Montgomery PS, Blevins SM. Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: a randomized controlled trial. J Am Heart Assoc. 2014 Sep 18;3(5):e001107. doi: 10.1161/JAHA.114.001107. PMID 25237048
  • Gardner AW, Bright BC, Ort KA, Montgomery PS. Dietary intake of participants with peripheral artery disease and claudication. Angiology. 2011 Apr;62(3):270-5. doi: 10.1177/0003319710384395. PMID 21406424

Identifiers

NCT: NCT03845036 · 16383 · R01AG070086-01A1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗